IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from November 03rd to November 07th 2025
       
Name of the issueIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1103/11/2025FR0010259150300122,60000AQEU
IPSEN549300M6SGDPB4Z94P1103/11/2025FR00102591501000122,59820CEUX
IPSEN549300M6SGDPB4Z94P1103/11/2025FR0010259150300122,40000TQEX
IPSEN549300M6SGDPB4Z94P1103/11/2025FR00102591502400122,29083XPAR
IPSEN549300M6SGDPB4Z94P1104/11/2025FR0010259150500123,60000AQEU
IPSEN549300M6SGDPB4Z94P1104/11/2025FR0010259150800123,56250CEUX
IPSEN549300M6SGDPB4Z94P1104/11/2025FR0010259150300123,70000TQEX
IPSEN549300M6SGDPB4Z94P1104/11/2025FR00102591502400122,55042XPAR
IPSEN549300M6SGDPB4Z94P1105/11/2025FR0010259150300123,30000AQEU
IPSEN549300M6SGDPB4Z94P1105/11/2025FR00102591501000123,45000CEUX
IPSEN549300M6SGDPB4Z94P1105/11/2025FR0010259150300123,20000TQEX
IPSEN549300M6SGDPB4Z94P1105/11/2025FR00102591502361123,81512XPAR
IPSEN549300M6SGDPB4Z94P1106/11/2025FR0010259150315122,41905AQEU
IPSEN549300M6SGDPB4Z94P1106/11/2025FR0010259150481122,40104CEUX
IPSEN549300M6SGDPB4Z94P1106/11/2025FR0010259150200122,30000TQEX
IPSEN549300M6SGDPB4Z94P1106/11/2025FR00102591502400122,66088XPAR
IPSEN549300M6SGDPB4Z94P1107/11/2025FR0010259150348122,76897AQEU
IPSEN549300M6SGDPB4Z94P1107/11/2025FR0010259150863122,96825CEUX
IPSEN549300M6SGDPB4Z94P1107/11/2025FR0010259150300123,00000TQEX
IPSEN549300M6SGDPB4Z94P1107/11/2025FR00102591502204123,05957XPAR
    19072122,92660 

Attachment



EN
12/11/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen announces the availability of its 2025 Universal Registration Do...

Ipsen announces the availability of its 2025 Universal Registration Document Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document has been filed today with the French Autorité des Marchés Financiers (AMF) and registered under the number D.26-0202. The document is available on and . Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France. The Universal Registration Document includes in particular: the Annual F...

21m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen annonce la mise à disposition de son Document d’enregistrement u...

Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025 Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025 PARIS, FRANCE, 1er AVRIL 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que son Document d’enregistrement universel 2025 a été déposé ce jour auprès de l’Autorité des Marchés Financiers (AMF) et enregistré sous le numéro D.26-0202. Ce document peut être consulté sur le site internet de la société à l’adresse et sur le site de l’AMF . Il sera également tenu à disposition au siège social de la Société – 70 rue Balard, 7...

21m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen showcases transformative potential of early immuno-oncology pipe...

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno‑modulation to deliver differentiated anti‑tumor activity PARIS, FRANCE, 18 ...

March 18, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen présente le potentiel transformateur de son pipeline d’immuno on...

Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en charge des tumeurs solides.ITGA2 identifié comme nouvelle cible de l’anticorps-conjugué (ADC) innovant IPN60300 d’Ipsen, fortement surexprimée dans de nombreux types de tumeurs solides.Ces données précliniques illustrent le potentiel croissant du portefeuille de médicaments expé...

March 18, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - February 2026 - Monthly information relative to the total numb...

Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of ...

March 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch